Abstract: Methods, systems, and devices for wireless communications are described. Generally, the described techniques provide for measuring, filtering, and reporting cross-link interference (CLI) in cases where not all aggressor user equipments (UEs) are transmitting signals that can be measured by a victim UE. A UE may obtain a set of CLI measurements by performing CLI measurements during a set of CLI measurement occasions. The UE may determine a first subset of the set of CLI measurements that satisfy a CLI measurement threshold and a second subset of the set of CLI measurements that do not satisfy the CLI measurement threshold. The UE may apply a filter to the first subset of the set of CLI measurements, and suppress the filter for the second subset of the set of CLI measurements, to obtain a filtered CLI measurement value. The UE may transmit the filtered CLI measurement value to a base station.

Abstract: According to examples, a learning based, end-to-end compression system may include an encoder, which may receive a complex hologram image and encode a latent code for a real component and an imaginary component of the hologram image. The system may also include a quantizer to quantize the latent code and a transform block, which may entropy-code the quantized latent code to obtain a compressed image. The system may further include a generator to decode the compressed image and a discriminator, which may classify the decoded image to obtain an uncompressed image. In case of holographic video input, the encoder may encode a frame to obtain a standard compressed frame and a residual to a latent code. The generator may decode the standard compressed frame and the latent code to obtain a reconstructed residual, and the discriminator may combine the uncompressed standard frame and the reconstructed residual.

Abstract: The present disclosure relates to compositions and methods for treating a subject having cancer associated with melanoma-associated antigen 4 (MAGE-A4) peptide. The disclosure includes the embodiments relate to a chimeric antigen receptor (CAR) that binds MAGE-A4 peptide, a polynucleotide encoding a CAR that binds the MAGE-A4 peptide, a modified cell comprising a CAR that binds the MAGE-A4 peptide, and a population of modified cells comprising a CAR that binds the MAGE-A4 peptide.

Abstract: Embodiments relate to a modified cell comprising a chimeric antigen receptor (CAR) and a dominant negative form of PD-1, wherein the dominant negative form of PD-1 lacks a functional PD-1 intracellular domain for PD-1/PD-L1 signal transduction, and the CAR comprises an antigen binding domain, a transmembrane domain, a co-stimulatory domain, and a CD3 zeta domain. The dominant negative form of PD-1 is regulated by an inducible gene expression system.

Abstract: A configuration of cross-carrier channel state information (CSI) reporting is disclosed. A user equipment (UE) may be configured for CSI reporting, which includes multiple trigger states, in which some of these trigger states include at least one carrier indicator identifying at least one component carrier (CC) for CSI measurement. Upon receipt of a downlink control information (DCI) message including identification of one of the trigger states, the UE identifies at least one CSI report configuration which may be identified with an associated CC and identification of at least one CSI resource setting identified with the CC for each of the CSI report configurations. The UE may then perform CSI measurement for the identified CC based on the CSI report configuration and resource setting. The UE may then signal the CSI report, including the CSI measurement, to a serving base station.

Abstract: Aspects described herein relate to receiving, from a node and using a serving beam for loop processing, at least a first signal in a synchronization signal burst set, and receiving, from the node and using a non-serving beam for beam sweeping, at least a second signal in the synchronization signal burst set.

Abstract: According to examples, a display system may include a head-mounted display (HMD) headset. The HMD may comprise at least one exterior-facing RBG camera mounted on a front face of the HMD and on a same visual plane of a user's eye. The at least one exterior-facing RBG camera may collects images for view synthesis. The HMD may include a processor, and a memory storing instructions, which when executed by the processor, cause the processor to provide view synthesis in accordance with a machine-learning (ML) based technique comprising at least one of the following: depth estimation, imaging to sharpening, forward splatting, disocclusion filtering, or fusion.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may indicate, to a base station, a capability of the UE to use a channel measurement resource for both a joint transmission hypothesis and a single transmission hypothesis. The UE may receive, based on indicating the capability of the UE, a configuration message indicating a first channel measurement resource that is associated with a first transmission configuration indicator state and that is configured for a first joint transmission hypothesis. The UE may obtain a channel measurement for both the first joint transmission hypothesis and a first single transmission hypothesis using the first channel measurement resource based on the configuration message.

Abstract: Embodiments of the present disclosure relate to compositions and methods of enhancing lymphocytes' ability to treat cancer patients. Embodiments relate to a polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR), a nucleic acid encoding an Oxygen-Dependent Degradation domain (ODD), and a nucleic acid encoding one or multiple sequences of Hypoxia-Response Element (HRE).

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.

Abstract: Embodiments relate to a modified cell comprising an antigen binding molecule, and the expression and/or function of one or more genes in the modified cell has been enhanced or reduced or eliminated. The one or more genes include CXCR3, SLC1A3, YAP, TIGIT, S1P1, and IL-35. In embodiments, the cell is a T cell, a dendritic cell, a NK cell, or a macrophage cell. In embodiments, the antigen binding molecule comprises a chimeric antigen receptor (CAR) and/or the second antigen binding molecule is a T Cell Receptor (TCR).

Abstract: Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.

Abstract: The present disclosure relates to a system for immune therapy, the system comprising a sample processing module configured to obtain whole blood from a subject; a cell incubation module configured to activate blood cells of the whole blood and/or introduce a vector into the blood cells of the whole blood; and a cell infusion module configured to infuse at least a portion of the whole blood to the subject, wherein the blood cells comprise CD3+ cells, NK cells, myeloid cells, and neutrophils.

Abstract: The present disclosure relates to compositions and methods for enhancing cell response and/or expanding chimeric antigen receptor (CAR) cells and/or maintenance in vivo and/or in vitro. In embodiments, the method comprises obtaining CAR T cells comprising a CAR comprising a binding domain that binds a solid tumor antigen, a transmembrane domain, and an intracellular domain; and contacting the CART cells with white blood cells and a bispecific antibody, such as a Bispecific T cell engager (BiTE®), thereby activating the CAR T cells, wherein the level of activation of the CAR T cells is higher than the level of activation of CAR T ells that are contacted with B cells without the bispecific antibody. The bispecific antibody comprises a first binding domain binding CD3 and a second binding domain binding CD19, CD20, CD22, or BCMA.

Abstract: Methods related to wireless communication systems and scheduling channel state information operations and transmissions. A user equipment (UE) receives, from a base station (BS), a channel state information (CSI) computation request. The UE then identifies a first CSI measurement resource based on the CSI computation request. The UE determines CSI based on the first CSI measurement resource, and receives, from the BS, a CSI report transmission request associated with the first CSI measurement resource. The UE optionally transmits to the BS a CSI report based on the first CSI measurement resource or a different CSI measurement resource. Other features are also claimed and described.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may transmit a communication that identifies one or more UE capability parameters for at least one of sounding reference signal reference signal received power measurement or cross-link interference (CLI) received signal strength indication measurement. The UE may receive a CLI measurement configuration that is based at least in part on the one or more UE capability parameters. Numerous other aspects are provided.

Abstract: Apparatus and associated methods relate to a one-piece structure for a solid electrolyte chemical sensor (SECS) having a first surface defining a cavity designed to receive a substrate that retains a solid electrolyte, an internal water impermeable coating on at least a portion of the first surface, a second surface that is substantially coplanar with an adjacent peripheral edge of a top surface of the substrate when the substrate is received in the cavity, and a plurality of electrical contacts disposed on the second surface adapted to electrically couple with the electrodes on the substrate when the substrate is received in the cavity and electrical paths are provided between respective electrical contacts and electrodes. In an illustrative example, the internal water impermeable coating may include a metallic material, such as gold. In various embodiments, the one-piece structure may advantageously prevent water loss from both the sensor substrate and the SECS.

Abstract: Methods, apparatuses and systems for providing gas detecting apparatuses (e.g., electrochemical detectors) are disclosed herein. An example gas detecting apparatus may comprise a sensing component comprising: a housing configured to receive a sample gaseous substance comprising a target gaseous substance and an interferent gaseous substance; a reference electrode, disposed within the housing; a counter electrode disposed within the housing; and a sensing electrode disposed within the housing that is operatively coupled to a bias voltage circuit.

Abstract: The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFN?.

Abstract: Methods, apparatuses and systems for providing gas detecting apparatuses (e.g., electrochemical detectors) are disclosed herein. An example gas detecting apparatus may comprise a sensing component comprising: a first sensing electrode configured to generate a first concentration level indication associated with a first portion of a sample gaseous substance disposed within the sensing component; and a second sensing electrode operatively coupled to a filtering element that is configured to absorb at least one substance from the sample gaseous substance, wherein the second sensing electrode is configured to generate a second concentration level indication associated with a second portion of the sample gaseous substance.